Repligen Form 4: Anthony Hunt option exercise and multiple sales disclosed
Rhea-AI Filing Summary
Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director exercised low-strike options and executed sizable sales, leaving meaningful vested option exposure.
The filing shows an option exercise at a $33.87 strike for 20,000 shares paired with substantial open-market dispositions executed under a 10(b)5-1 plan at prices between ~$116 and ~$122. The exercise converted low-cost option economics into shares, while the sales monetized a portion of equity at multi-year high price bands. Post-transaction direct common shares are reported at 100,743 while option-based beneficial ownership totals 182,344 shares, with remaining vesting schedules disclosed.
TL;DR: Transactions appear compliant and documented; sales were conducted under a pre-established 10(b)5-1 plan.
The Form 4 discloses use of a 10(b)5-1 trading plan adopted December 9, 2024, for the reported sales and includes weighted-average prices and a commitment to provide detailed per-tranche pricing on request. The signature by an attorney-in-fact indicates the filing was executed via authorized representative. Vesting schedules for remaining option shares are explicitly stated, supporting transparency about future potential dilution or insider holdings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $33.87 | $677K |
| Sale | Common Stock | 96 | $116.34 | $11K |
| Sale | Common Stock | 1,108 | $118.32 | $131K |
| Sale | Common Stock | 3,262 | $119.64 | $390K |
| Sale | Common Stock | 14,882 | $120.19 | $1.79M |
| Sale | Common Stock | 7,584 | $121.42 | $921K |
| Sale | Common Stock | 2,179 | $122.23 | $266K |
Footnotes (1)
- Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. $118.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.80 to $118.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $119.64 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.83 to $119.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $120.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.85 to $120.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $121.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.86 to $121.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $122.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027.
